Terminal Delirium - Haloperidol and Nonpharmacologic Care

Key Points

• Terminal delirium is common and often multifactorial.
• The diagnostic burden should match goals and expected benefit.
• Treat low-burden reversible causes such as retention, constipation, pain, and medication toxicity.
• Nonpharmacologic calming remains important.
• Antipsychotics are symptom-control options in selected severe agitation, not proven cures for delirium.
• Benzodiazepines can worsen routine delirium but may be useful for withdrawal or refractory terminal agitation.
• Refractory suffering may justify proportionate palliative sedation under a formal framework.
• Family education reduces distress and misinterpretation of delirious behavior.

Algorithm

1. Confirm acute fluctuating cognitive change and assess distress.
2. Review goals and whether reversible-cause evaluation is appropriate.
3. Check pain, bladder, bowel, medication toxicity, and environmental triggers.
4. Use calm familiar surroundings and reduce unnecessary stimulation.
5. Treat severe distressing agitation with an individualized medication plan.
6. Reassess comfort and adverse effects rather than aiming for cognitive normalization.
7. Escalate to palliative-sedation framework only for refractory suffering.
8. Support family and continue basic comfort care.

Clinical Synopsis & Reasoning

Delirium in the last days or weeks of life can result from organ failure, dehydration, infection, medications, opioid neurotoxicity, metabolic disturbance, urinary retention, constipation, or direct neurologic disease. The clinical question differs from routine inpatient delirium because exhaustive diagnostic testing may not benefit a dying patient whose goal is comfort. Assess whether a reversible contributor can be corrected with low burden and meaningful expected benefit. A bladder scan and relief of retention, bowel treatment, medication simplification, or opioid rotation can provide more comfort than broad laboratory testing.

Differentiate agitated delirium from uncontrolled pain, panic, akathisia, medication withdrawal, or a need to urinate. Family reports about the patient's usual behavior can help. Hallucinations are not automatically distressing; medication is not required if the patient is calm. Nonpharmacologic care includes a quiet familiar setting, gentle reorientation when welcomed, limiting room changes, minimizing alarms, preserving hearing and vision aids, and keeping trusted people nearby. As death approaches, repeated correction of the patient's perceptions can sometimes increase distress, so supportive presence may be preferable.

Medication decisions should be symptom-driven. Evidence for antipsychotics in palliative delirium is mixed, and they should not be presented as disease-modifying therapy. They may still be used in selected patients with severe agitation, dangerous behavior, or distressing psychotic symptoms after reversible factors have been considered. Benzodiazepines can worsen ordinary delirium but may be useful for alcohol or benzodiazepine withdrawal and can be added in refractory terminal agitation when sedation is an accepted goal.

Treatment Strategy & Disposition

Treat pain, urinary retention, constipation, medication toxicity, and other low-burden reversible causes. Review anticholinergics, corticosteroids, stimulants, and sedatives. If opioid-induced neurotoxicity is suspected, reduce or rotate the opioid and correct dehydration when appropriate. For severe agitation, local palliative protocols may use haloperidol or another antipsychotic at low doses, with titration to comfort rather than normal cognition. Consider QT risk and extrapyramidal effects when these concerns remain clinically relevant.

When agitation remains refractory near death, a benzodiazepine such as midazolam or lorazepam may be added as part of proportionate symptom relief under palliative guidance. If continuous sedation becomes necessary for otherwise refractory suffering, use a formal palliative-sedation framework with clear documentation of indication, goals, consent or surrogate involvement, proportionality, and ongoing basic comfort care.

Support family members by explaining that delirium is common near death and that statements or behaviors may not reflect the patient's enduring beliefs. Prepare them for fluctuating alertness and the possibility that comfort medications can increase sleep. Continue mouth care, repositioning for comfort, bowel and bladder care, and treatment of pain even when the patient becomes less interactive.

Epidemiology / Risk Factors

• Delirium is common in the final phase of advanced cancer and other terminal illnesses.
• Risk rises with organ failure, dehydration, high medication burden, and neurologic disease.
• Hyperactive symptoms are more visible, but hypoactive delirium also occurs.
• Caregiver distress can be substantial when behavior changes abruptly.

Investigations

Medication Considerations

Pharmacology

Prognosis / Complications

• Some episodes improve when a reversible trigger is corrected.
• In actively dying patients, delirium may persist until death despite treatment.
• Comfort can usually be improved even when cognition cannot be restored.
• Refractory agitation is an indication for specialist palliative support.

Patient Education / Counseling

• Explain that delirium is a medical change in brain function, not intentional behavior.
• Encourage calm presence and familiar voices without arguing about misperceptions.
• Prepare family for increasing sleep if sedating medication is needed.
• Discuss which investigations or treatments no longer fit comfort goals.
• Provide a contact plan for uncontrolled agitation or distress at home.

Notes

Terminal delirium should be treated according to suffering, not according to how abnormal the behavior looks to observers. A patient who is awake but frightened and pulling at lines may need rapid symptom control, while a quiet patient describing a benign vision may need only reassurance. Remove nonessential monitoring and invasive devices when they no longer contribute to comfort.

When terminal delirium occurs at home or in a facility, anticipatory prescribing and caregiver instructions are especially important. The plan should specify which medication to use first, when a second dose is appropriate, which behaviors represent distress rather than harmless confusion, and when to call the hospice or palliative team. Avoid leaving several sedating PRN medications without a sequence, because frightened caregivers may either undertreat severe agitation or combine agents unsafely. A simple written escalation pathway can reduce emergency transfers while preserving comfort.

References

1. European Association for Palliative Care: Palliative Sedation — Link